BMO Capital analyst Gary Nachman reiterated an Outperform rating and $80 price target on Sage Therapeutics (NASDAQ: SAGE) hit its most important milestone as a company to date with very positive data for Brexanolone in two Phase 3 studies in post-partum depression.

Nachman said the results are "encouraging and enable SAGE to file in the US and Europe, and we see a high probability of approval."

Further, he said the data could potentially bode well for the anticipated SAGE-217 results in both MDD (4Q17) and PPD (1Q18)

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $62.66 yesterday.

Analyst Comments

Chardan Capital Markets Upgrades Sage Therapeutics (SAGE) to BuyNovember 10, 2017 8:16 AM Sage Therapeutics (SAGE) PT Raised to $140 at Canaccord GenuityNovember 10, 2017 7:22 AM Sage Therapeutics (SAGE) PT Raised to $135 at CowenNovember 9, 2017 3:20 PM Sage Therapeutics (SAGE) PT Raised to $105 at StifelNovember 9, 2017 12:43 PM Sage Therapeutics (SAGE) PT Raised to $123 at Leerink PartnersNovember 9, 2017 12:13 PM Sage Therapeutics (SAGE) PT Raised to $100 at Needham & CompanyNovember 9, 2017 11:34 AM SAGE Therapeutics (SAGE): Primary Endpoints in Both Phase III PPD Trials Met - SuntrustNovember 9, 2017 7:17 AM SAGE Therapeutics (SAGE) Climbs 50% After Phase 3 Study to Treat Postpartum Depression Meets Primary EndpointNovember 9, 2017 6:42 AM SAGE Therapeutics (SAGE) Says Brexanolone Achieved Primary Endpoints in Both Phase 3 Trials in Postpartum DepressionNovember 9, 2017 6:28 AM Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum DepressionNovember 9, 2017 6:00 AM